Etirinotecan pegol, a long-acting Top1 inhibitor designed to provide sustained exposure to SN38, was developed with the aim of providing increased anti-tumor activity and a better safety profile compared with short-acting Top1 inhibitors. The gene discussed is TOP1; the disease is neoplasm.